echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The federal court of Germany confirmed that Wuxi heskell company violated the German patent part of Echosens

    The federal court of Germany confirmed that Wuxi heskell company violated the German patent part of Echosens

    • Last Update: 2020-02-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Echosens19 announced that it has received a favorable ruling from the German Federal Court of Karlsruhe, which enjoys high prestige in the world, on the patent infringement case filed by Echosens against China Wuxi haiskel Medical Technology Co., Ltd since November 2015 On February 4, 2020, the federal court rejected the request for reexamination made by haiskel Corporation of Wuxi, China, to the higher court of Dusseldorf On March 1, 2018, the higher court of Dusseldorf confirmed the first ruling made by the judge on April 20, 2017, that haiskel violated the German part of Echosens patent ep1169636b1 All marketing, sales and commercial uses of hisky / fibrotouch were found illegal in Germany as a result of the federal court's ruling that hisky's products were infringing "We have pioneered vibration controlled transient elastic imaging technology for liver assessment and invested heavily in our innovative technology, with more than one third of our employees engaged in research and development Echosens technology is unique and supported by more than 2500 clinical studies, so we cannot allow competitors to fake our technological breakthroughs or infringe our patents, "said Laurent sandrin, founder and chief technology officer of Echosens "We are pleased that the court ruled that Haskell violated Echosens's patent As a leader in noninvasive diagnosis of liver health, Echosens is committed to protecting its intellectual property rights to advance its mission of expanding and improving liver health assessment and diagnosis worldwide, "said Dominique LeGros, CEO of the Echosens group (Note: the original text has been deleted) 37
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.